Literature DB >> 23148191

Pheochromocytoma - update on disease management.

Roland Därr, Jacques W M Lenders, Lorenz C Hofbauer, Bernd Naumann, Stefan R Bornstein, Graeme Eisenhofer.   

Abstract

Pheochromocytomas are rare endocrine tumors that can present insidiously and remain undiagnosed until death or onset of clear manifestations of catecholamine excess. They are often referred to as one of the 'great mimics' in medicine. These tumors can no longer be regarded as a uniform disease entity, but rather as a highly heterogeneous group of chromaffin cell neoplasms with different ages of onset, secretory profiles, locations, and potential for malignancy according to underlying genetic mutations. These aspects all have to be considered when the tumor is encountered, thereby enabling optimal management for the patient. Referral to a center of specialized expertise for the disease should be considered wherever possible. This is not only important for surgical management of patients, but also for post-surgical follow up and screening of disease in patients with a hereditary predisposition to the tumor. While preoperative management has changed little over the last 20 years, surgical procedures have evolved so that laparoscopic resection is the standard of care and partial adrenalectomy should be considered in all patients with a hereditary condition. Follow-up testing is essential and should be recommended and ensured on a yearly basis. Managing such patients must now also take into account possible underlying mutations and the appropriate selection of genes for testing according to disease presentation. Patients and family members with identified mutations then require an individualized approach to management. This includes consideration of distinct patterns of biochemical test results during screening and the appropriate choice of imaging studies for tumor localization according to the mutation and associated differences in predisposition to adrenal, extra-adrenal and metastatic disease.

Entities:  

Keywords:  clinical presentation; diagnosis; follow up; genetic testing; management; paraganglioma; pheochromocytoma; treatment

Year:  2012        PMID: 23148191      PMCID: PMC3474647          DOI: 10.1177/2042018812437356

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  160 in total

1.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

Authors:  B E Baysal; R E Ferrell; J E Willett-Brozick; E C Lawrence; D Myssiorek; A Bosch; A van der Mey; P E Taschner; W S Rubinstein; E N Myers; C W Richard; C J Cornelisse; P Devilee; B Devlin
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  Mydriasis and acute pulmonary oedema complicating laparoscopic removal of phaechromocytoma.

Authors:  P Tauzin-Fin; G Hilbert; M Krol-Houdek; P Gosse; P Maurette
Journal:  Anaesth Intensive Care       Date:  1999-12       Impact factor: 1.669

3.  Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy: this statement was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), September 2007. It was prepared by the SAGES Guidelines Committee.

Authors:  Hori Yumi
Journal:  Surg Endosc       Date:  2008-02-21       Impact factor: 4.584

4.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

5.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.

Authors:  D Astuti; F Latif; A Dallol; P L Dahia; F Douglas; E George; F Sköldberg; E S Husebye; C Eng; E R Maher
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

6.  6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma.

Authors:  K Pacak; G Eisenhofer; J A Carrasquillo; C C Chen; S T Li; D S Goldstein
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

7.  The case for laparoscopic adrenalectomy.

Authors:  I S Gill
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

8.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..

Authors:  Stefan Hoegerle; Egbert Nitzsche; Carsten Altehoefer; Nadir Ghanem; Tanja Manz; Ingo Brink; Martin Reincke; Ernst Moser; Hartmut P H Neumann
Journal:  Radiology       Date:  2002-02       Impact factor: 11.105

9.  Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma.

Authors:  S Yoshida; M Hatori; T Noshiro; N Kimura; S Kokubun
Journal:  Arch Orthop Trauma Surg       Date:  2001-11       Impact factor: 3.067

10.  Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.

Authors:  Tomás Zelinka; Henri J L M Timmers; Anna Kozupa; Clara C Chen; Jorge A Carrasquillo; James C Reynolds; Alexander Ling; Graeme Eisenhofer; Ivica Lazúrová; Karen T Adams; Millie A Whatley; Jirí Widimsky; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

View more
  19 in total

Review 1.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

2.  Absence of BRAF mutation in pheochromocytoma and paraganglioma.

Authors:  T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

3.  Pelvic pheochromocytoma: a rare lethal tumor initially presenting as tuboovarian mass to gynaecologist.

Authors:  Santosh Kumar; Arawat Pushkarna; Gautam R Choudhary; Seema Prasad; Sudheer K Devana
Journal:  J Obstet Gynaecol India       Date:  2013-09-27

Review 4.  Carotid baroreflex activation therapy for resistant hypertension.

Authors:  Ronald G Victor
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

5.  The evaluation and treatment of endocrine forms of hypertension.

Authors:  Alejandro Velasco; Wanpen Vongpatanasin
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

Review 6.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

7.  Elemental Composition of Pheochromocytoma Resolved on Solid/Adrenal Tissue and Whole Blood Level.

Authors:  Jovana Jagodić; Branislav Rovčanin; Ivan Paunović; Mladen Mihailović; Nebojša Zečević; Dragan Manojlović; Aleksandar Stojsavljević
Journal:  Biol Trace Elem Res       Date:  2021-10-06       Impact factor: 3.738

8.  Functional paraganglioma.

Authors:  Gokulakrishnan Balasubramanian; Vallikantha Nellaiappan
Journal:  BMJ Case Rep       Date:  2014-02-20

9.  Largest pheochromocytoma reported in Canada: A case study and literature review.

Authors:  Druvtej Ambati; Kunal Jana; Trustin Domes
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

10.  Treatment-resistant hypertension in a post-transplant patient with cystic fibrosis: a rare case of phaeochromocytoma.

Authors:  David Joseph Tansey; Jim John Egan; Michelle Murray; Katie Padfield; John Conneely; Mensud Hatunic
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.